GSTM1 and anemia (phenotype): Increased rates of anaemia have been reported in two IPTi trials [9,11], however, the majority of RCTs of IPTi have reported a decline [7,8,12], or no effect [10], with results of the pooled analysis showing a 22% decline in severe anaemia (Hb < 8 g/dL) [5].